Alexander J. Thompson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alexander J. Thompson has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Dieguez
Merck, Sharpe, and Dohme, Corp, Whitehouse Station, NJ, USA
1 shared publication - Hans Ludger Tillmann
Division of Gastroenterology, Hepatology & Nutrition, Department of Medicine East Carolina University Greenville North Carolina USA
1 shared publication - J. Will Thompson
Move Analytical LLC, Carrboro, NC
1 shared publication - Jacques Fellay
School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland; Precision Medicine Unit, Biomedical Data Science Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
1 shared publication - Jeanette J. McCarthy
Duke University Medical Center
1 shared publication John G. McHutchison
Duke University Medical Center
1 shared publication
Latest Publications
- Open Access
- 4 May 2012
- Published by Springer Nature in BMC Bioinformatics
- Vol. 13 (1) , 74
Metaprotein expression modeling for label-free quantitative proteomics
Label-free quantitative proteomics holds a great deal of promise for the future study of both medicine and biology. However, the data generated is extremely intricate in its correlation structure, and its proper analysis is complex. There are issues with missing identifications. There are high levels of correlation between many, but not all, of the peptides derived from the same protein. Additionally, there may be systematic shifts in the sensitivity of the machine between experiments or even through time within the duration of a single experiment. We describe a hierarchical model for analyzing unbiased, label-free proteomics data which utilizes the covariance of peptide expression across samples as well as MS/MS-based identifications to group peptides—a strategy we call metaprotein expression modeling. Our metaprotein model acknowledges the possibility of misidentifications, post-translational modifications and systematic differences between samples due to changes in instrument sensitivity or differences in total protein concentration. In addition, our approach allows us to validate findings from unbiased, label-free proteomics experiments with further unbiased, label-free proteomics experiments. Finally, we demonstrate the clinical/translational utility of the model for building predictors capable of differentiating biological phenotypes as well as for validating those findings in the context of three novel cohorts of patients with Hepatitis C. Mass-spectrometry proteomics is quickly becoming a powerful tool for studying biological and translational questions. Making use of all of the information contained in a particular set of data will be critical to the success of those endeavors. Our proposed model represents an advance in the ability of statistical models of proteomic data to identify and utilize correlation between features. This allows validation of predictors without translation to targeted assays in addition to informing the choice of targets when it is appropriate to generate those assays.
- 4 May 2012
- Published by Springer Nature in BMC Bioinformatics
- Vol. 13 (1) , 74
Open AccessMetaprotein expression modeling for label-free quantitative proteomics
Label-free quantitative proteomics holds a great deal of promise for the future study of both medicine and biology. However, the data generated is extremely intricate in its correlation structure, and its proper analysis is complex. There are issues with missing identifications. There are high levels of correlation between many, but not all, of the peptides derived from the same protein. Additionally, there may be systematic shifts in the sensitivity of the machine between experiments or even through time within the duration of a single experiment. We describe a hierarchical model for analyzing unbiased, label-free proteomics data which utilizes the covariance of peptide expression across samples as well as MS/MS-based identifications to group peptides—a strategy we call metaprotein expression modeling. Our metaprotein model acknowledges the possibility of misidentifications, post-translational modifications and systematic differences between samples due to changes in instrument sensitivity or differences in total protein concentration. In addition, our approach allows us to validate findings from unbiased, label-free proteomics experiments with further unbiased, label-free proteomics experiments. Finally, we demonstrate the clinical/translational utility of the model for building predictors capable of differentiating biological phenotypes as well as for validating those findings in the context of three novel cohorts of patients with Hepatitis C. Mass-spectrometry proteomics is quickly becoming a powerful tool for studying biological and translational questions. Making use of all of the information contained in a particular set of data will be critical to the success of those endeavors. Our proposed model represents an advance in the ability of statistical models of proteomic data to identify and utilize correlation between features. This allows validation of predictors without translation to targeted assays in addition to informing the choice of targets when it is appropriate to generate those assays.
- 14 February 2010
- Published by Springer Nature in Current Hepatitis Reports
- Vol. 9 (1) , 1-8
How the Human Genome Can Predict Response to Hepatitis C Therapy
- 14 February 2010
- Published by Springer Nature in Current Hepatitis Reports
- Vol. 9 (1) , 1-8
How the Human Genome Can Predict Response to Hepatitis C Therapy